The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Abstract
CONTEXT: Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding. OBJECTIVES: Our objectives were to confirm weight loss with dapagliflozin and establish through body composition measurements whether weight loss is accounted for by changes in fat or fluid components. DESIGN AND SETTING: This was a 24-wk, international, multicenter, randomized, parallel-group, double-blind, placebo-controlled study with ongoing 78-wk site- and patient-blinded extension period at 40 sites in five countries. PATIENTS: Included were 182 patients with T2DM (mean values: women 63.3 and men 58.6 yr of age; hemoglobin A1c 7.17%, body mass index 31.9 kg/m2, and body weight 91.5 kg) inadequately controlled on metformin. INTERVENTION: Dapagliflozin 10 mg/d or placebo was added to open-label metformin for 24 wk. MAIN OUTCOME MEASURES: Primary endpoint was total body weight (TBW) change from baseline at wk 24. Key secondary endpoints were waist circumference and dual-energy x-ray absorptiometry total-body fat mass (FM) changes from baseline at wk 24, and patient proportion achieving body weight reduction of at least 5% at wk 24. In a subset of patients, magnetic resonance assessment of visceral adipose tissue (VAT) and sc adipose tissue (SAT) volume and hepatic lipid content were also evaluated. RESULTS: At wk 24, placebo-corrected changes with dapagliflozin were as follows: TBW, -2.08 kg [95% confidence interval (CI)=-2.84 to -1.31; P<0.0001]; waist circumference, -1.52 cm (95% CI=-2.74 to -0.31; P=0.0143); FM, -1.48 kg (95% CI=-2.22 to -0.74; P=0.0001); proportion of patients achieving weight reduction of at least 5%, +26.2% (95% CI=15.5 to 36.7; P<0.0001); VAT, -258.4 cm3 (95% CI=-448.1 to -68.6; nominal P=0.0084); SAT, -184.9 cm3 (95% CI=-359.7 to -10.1; nominal P=0.0385). In the dapagliflozin vs. placebo groups, respectively, serious adverse events were reported in 6.6 vs. 1.1%; events suggestive of vulvovaginitis, balanitis, and related genital infection in 3.3 vs. 0%; and lower urinary tract infections in 6.6 vs. 2.2%. CONCLUSIONS: Dapagliflozin reduces TBW, predominantly by reducing FM, VAT and SAT in T2DM inadequately controlled with metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Grundy, S. M. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.151092 · Cited by 1,616
de Koning, L., Merchant, A. T., Pogue, J., & Anand, S. S. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm026 · Cited by 1,073
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 873
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 725
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629
Flagged first, then by citations
Research works printed but not linked: 1
- Tang, 2003, The financing burden of treatment of diabetes-II and its symptom in urban China., Chin Health Econ, 12, 21
Cited by
Sorted by citations
Items 601–700 of 864
Overview of Metabolic Syndrome
Ahima, R. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_1-1 · Cited by 7
Messana, J. M., Schwartz, S. S., & Townsend, R. R. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s105721 · Cited by 7
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes
Al-Bazz, D. Y., & Wilding, J. P. H. (2020) · Future Cardiology · doi:10.2217/fca-2019-0065 · Cited by 8
Self-citationSandoval, A. F. B., & Vallejo, C. A. S. (2020) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2019.12.003 · Cited by 7
Watanabe, Y., Suzuki, D., Kuribayashi, N., Uchida, D., Kato, M., Ohashi, H., Nagayama, D., Yamaguchi, T., Ohira, M., Saiki, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90879-z · Cited by 8
Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
Hage, L. E., Kashyap, S. R., & Rao, P. (2019) · Journal of Primary Care & Community Health · doi:10.1177/2150132719895188 · Cited by 6
Kashima, A., Kamiya, K., Hamazaki, N., Ueno, K., Nozaki, K., Ichikawa, T., Yamashita, M., Uchida, S., Noda, T., Hotta, K., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195956 · Cited by 6
de la Flor, J. C., Morales, B. C., Velasco, E. B., Hernandez, M. R., González-Mariño, R. Z., Tudero, C. R., Benites-Flores, I. R., Espinoza, C. V., Terrones, M. C., Guldris, S. C., et al. (2024) · Medicina · doi:10.3390/medicina60122096 · Cited by 8
Iordan, L., Lazăr, S., Timar, R. Z., Popescu, S. D., Sorescu, T., Albai, O., Braha, A., Timar, B., & Gaiţă, L. (2025) · Medicina · doi:10.3390/medicina61020209 · Cited by 9
Reducing Alzheimer’s disease risk with SGLT2 inhibitors: From glycemic control to neuroprotection
Alami, M., Morvaridzadeh, M., Khayari, A. E., Boumezough, K., Fatimy, R. E., Khalil, A., Fülöp, T., & Berrougui, H. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102751 · Cited by 6
Schwartz, S. S., & Katz, A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s65588 · Cited by 7
Cada, D. J., Levien, T. L., & Baker, D. E. (2014) · Hospital Pharmacy · doi:10.1310/hpj4907-647 · Cited by 6
Kudo, A., Machii, N., Ono, T., Saito, H., Oshiro, Y., Takahashi, R., Oshiro, K., Taneda, Y., Higa, M., Nakachi, K., et al. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003302 · Cited by 6
Taha, M., Elazab, S. T., Qutub, A., Abdelbagi, O., Baokbah, T. A. S., Gomaa, A. S., Zaghloul, R. A., Albarakati, A. J. A., Qusty, N. F., Babateen, O., et al. (2023) · Journal of Investigative Surgery · doi:10.1080/08941939.2023.2266736 · Cited by 6
Bando, N., Nakayama, N., Kashiwa, K., Horike, R., Fujimoto, A., Egawa, M., Adachi, M., Saji, H., Kira, B., Nakayama, K., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22245 · Cited by 6
Renal Sodium-Glucose Transporter-2 Inhibitors as Antidiabetic Agents
Nair, A. S., Bagchi, D., Lehmann, T. E., & Nair, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812019-4.00016-7 · Cited by 6
Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options
Demarchi, A., Somaschini, A., Cornara, S., & Androulakis, E. S. (2020) · Current Pharmaceutical Design · doi:10.2174/1389201021666201126143217 · Cited by 7
Prybyla, О. В. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.4.2021.237342 · Cited by 6
Diabetes: how to manage overweight and obesity in type 2 diabetes mellitus
Wesling, M., & D’Souza, J. J. (2022) · Drugs in Context · doi:10.7573/dic.2021-11-7 · Cited by 9
Bunyatyan, N. D., Бухтиярова, И. П., Дроговоз, С. М., Кононенко, А. В., Olefir, Y. V., Prokofiev, A. B., Анатольевна, П. И., & Goryachev, D. V. (2017) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-017-1621-4 · Cited by 8
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes
Aharon‐Hananel, G., & Raz, I. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1583210 · Cited by 6
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
Kataria, A., & Argyropoulos, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_25 · Cited by 6
Sharma, M., Nayar, R., Graham, Y., Parretti, H. M., Abbott, S., Tahrani, A., Miras, A. D., Madhok, B., Singhal, R., & Mahawar, K. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06044-6 · Cited by 5
Luo, Y., Bai, R., Zhang, W., & Qin, G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1333624 · Cited by 7
Therapeutic Repurposing of Antidiabetic Drugs in Diabetes-associated Comorbidities
Pathak, K., Pathak, M. P., Saikia, R., Gogoi, U., Das, R. J., Patowary, P., Kaishap, P. P., Bordoloi, S., Das, J., Sarma, H., et al. (2023) · Current Drug Therapy · doi:10.2174/1574885518666230516150404 · Cited by 6
Overview of Metabolic Syndrome
Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_1 · Cited by 5
Hu, Q., Yang, S., Zhang, B., & Su, N. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-01950-y · Cited by 6
Radellini, S., Vigneri, E., Guarnotta, V., Pantò, F., & Giordano, C. S. D. S. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01056-4 · Cited by 5
Igarashi, H., Uchino, H., Kanaguchi, M., Hisanaga, K., Sato, G., Yoshikawa, F., Furuta, M., Washizawa, N., Usui, S., Miyagi, M., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-00990-6 · Cited by 5
Boutsikos, I., Beltsios, E. T., Schmack, B., Pantazopoulos, I. N., & Chatzis, D. (2023) · Heart International · doi:10.17925/hi.2023.17.2.12 · Cited by 5
Czarnecka, P., Czarnecka, K., & Tronina, O. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13102828 · Cited by 5
Dapagliflozina: Más allá del control glucémico en el tratamiento de la diabetes mellitus tipo 2
Sanz-Serra, P., Pedro‐Botet, J., Roux, J. A. F., Benaiges, D., & Chillarón, J. J. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2014.11.001 · Cited by 5
New Perspectives on the Development of Antiobesity Drugs
Costantino, L., & Barlocco, D. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.167 · Cited by 5
Kakuda, H., Kobayashi, J., Sakurai, M., Kakuda, M., & Takekoshi, N. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2806w · Cited by 5
Sodium–Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus
Dalan, R. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000201 · Cited by 5
Choosongsang, P., & Soonthornpun, S. (2021) · Diabetic Medicine · doi:10.1111/dme.14659 · Cited by 6
Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes
Bilal, A., & Pratley, R. E. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.10.010 · Cited by 5
Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
Mankieva, E., & Ивановна, К. Е. (2023) · Russian Journal of Evidence-Based Gastroenterology · doi:10.17116/dokgastro202312041103 · Cited by 5
Overview of Metabolic Syndrome
Ahima, R. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_1 · Cited by 6
Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 Diabetes
Reutens, A. T., Lekamlage, D. H., Salim, A., Shaw, J. E., Esler, M., Cooper, M. E., & Kaye, D. M. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102304 · Cited by 4
Moreno-Lopez, M., Louvet, I., Delalleau, N., Acosta-Montalvo, A., Thévenet, J., Pasquetti, G., Gmyr, V., Kerr-Conte, J. A., Pattou, F. N., Bonner, C., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16089 · Cited by 4
Amawi, H. A., Makhlouf, T., Hammad, A. M., Alsheyab, S., Alhazaimeh, R., Hall, F. S., Khan, J. T., Al‐Trad, B., & Tiwari, A. K. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111414 · Cited by 5
Qiao, X., Wang, W., Cao, J., Guo, L., & Pan, Q. (2026) · Obesity Reviews · doi:10.1111/obr.70100 · Cited by 4
Schubert, A., Buchholt, A. T., Khoury, A. C. E., Kamal, A., & Taieb, V. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1310091 · Cited by 4
Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
Kourtidou, C., & Τζιόμαλος, Κ. (2023) · Biomedicines · doi:10.3390/biomedicines11020496 · Cited by 6
Popoviciu, M. S., Salmen, T., Reurean‐Pintilei, D., Voiculescu, V. M., & Stoian, A. P. (2025) · Medicina · doi:10.3390/medicina61030548 · Cited by 5
Dapagliflozin: NICE guidance for use in combination therapy for the treatment of type 2 diabetes
Al‐Mrayat, M., & Vloemans, M. (2013) · Practical Diabetes · doi:10.1002/pdi.1779 · Cited by 4
Dapagliflozin for the treatment of Type 2 diabetes
Woo, V. C., & Ho, J. D. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.950226 · Cited by 4
ROLE AND PLACE OF DAPAGLIFLOZIN IN THE MANAGEMENT OF 2nd TYPE DIABETES: FROM THEORY TO PRACTICE
Khalimov, Y. S., Агафонов, П. В., & Kuzmich, V. G. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-3-22-30 · Cited by 6
Monda, V. M., Porcellati, F., Strollo, F., Fucili, A., Monesi, M., Satta, E., & Gentile, S. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01791-x · Cited by 5
Vertical Sleeve Gastrectomy Lowers SGLT2/ Slc5a2 Expression in the Mouse Kidney
Akalestou, E., López–Noriega, L., Tough, I. R., Hu, M., Leclerc, I., Cox, H. M., & Rutter, G. A. (2022) · Diabetes · doi:10.2337/db21-0768 · Cited by 5
Schneider, C. A., & Pfister, R. (2022) · Herz · doi:10.1007/s00059-022-05134-6 · Cited by 4
Kalra, S., & Bhattacharya, S. (2022) · Journal of Diabetology · doi:10.4103/jod.jod_129_21 · Cited by 4
Hu, S., Lin, C., Cai, X., Zhu, X., Lv, F., Yang, W., & Ji, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1018720 · Cited by 4
Afrăsânie, I., Matei, I. T., Leancă, S. A., Chetran, A., Costache, A. D., Afrăsânie, V.-A., Dmour, B.-A., Crișu, D., Bădescu, M. C., Șerban, L., et al. (2023) · Life · doi:10.3390/life13020443 · Cited by 4
What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
Evans, M., Morgan, A. R., & Yousef, Z. R. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00678-z · Cited by 4
Zhao, S., Zhou, L., Tao, Y., Yue, Y., Wang, J., Shen, L., Lu, G., & Hang, Y. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-00999-5 · Cited by 4
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
Mordi, I. R., & Lang, C. C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.004 · Cited by 5
Davis, P. N., Ndefo, U. A., & Oliver, A. (2015) · Journal of Pharmacy Practice · doi:10.1177/0897190014566308 · Cited by 4
Cada, D. J., Cong, J., & Baker, D. E. (2015) · Cited by 4
Dapagliflozin combination therapy in type 2 diabetes mellitus
Yacoub, T. G. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2016.1111119 · Cited by 4
Ohara, N., Minami, I., Bouchi, R., Izumiyama, H., Hashimoto, K., Yoshimoto, T., & Ogawa, Y. (2017) · Diabetology International · doi:10.1007/s13340-017-0325-z · Cited by 4
Çalapkulu, M., Cander, S., Gül, Ö. Ö., & Ersoy, C. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.09.005 · Cited by 4
Watanabe, Y., Kuribayashi, N., Uchida, D., Suzuki, D., Kato, M., Nagayama, D., Ohashi, H., Ohira, M., Saiki, A., & Tatsuno, I. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0555-5 · Cited by 4
Watanabe, Y., Kuribayashi, N., Uchida, D., Suzuki, D., Kato, M., Nagayama, D., Ohashi, H., Ohira, M., Saiki, A., & Tatsuno, I. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00757-6 · Cited by 4
SGLT2 inhibitors: Exploring the effects in humans and horses
Sundra, T., Matthews, V. B., Harris, P. A., & Rendle, D. I. (2024) · Equine Veterinary Education · doi:10.1111/eve.14071 · Cited by 3
Matuszewski, W., Tomaszek, L., Szklarz, M., Górny, J. M., Kordas, B., Rutkowska, J., & Juranek, J. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186348 · Cited by 3
Kutoh, E., Kuto, A. N., Okada, R., & Urushibara, N. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04573-2 · Cited by 3
Teng, Y., Bian, W., Li, Q., Eyk, J. E. V., Yan, X., & Zhang, S. Y. (2026) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2026-0043 · Cited by 3
Rakhsha, S. S., Shahinfar, H., Ebrahimi-Mousavi, S., Kosari, A., Aali, Y., Mirzababaei, A., Hosseini, S. A., Jadidi, P., Shafiee, G., Mansourzadeh, M. J., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70957 · Cited by 3
Sridharan, K., & Sivaramakrishnan, G. (2026) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2026.103452 · Cited by 3
The therapeutic approach to cardiovascular–kidney–metabolic syndrome
Rangaswami, J., Lo, K. B., & Ndumele, C. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01109-6 · Cited by 3
Ertuğrul, D. T., Kan, E., TURA, Ç. B., Tugtekin, H. B., Ayakta, H., ÇELEBİOĞLU, M., Yılmaz, C., ÜTEBAY, O., Yetkin, İ., The DAPATURK Study Group, et al. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-00954-4 · Cited by 3
Zhang, A., Kalil, R. K., Marzec, A., Coulter, S., Virani, S. S., Patel, K. V., & Segar, M. W. (2024) · Texas Heart Institute Journal · doi:10.14503/thij-23-8375 · Cited by 4
Vargas-Ramírez, C. U., Posadas-Posadas, V., Ochoa-Précoma, R., Porchia, L. M., Pérez-Fuentes, R., & González-Mejía, M. E. (2024) · Diabetology International · doi:10.1007/s13340-024-00765-y · Cited by 4
Dapagliflozin: drug profile and its role in individualized treatment
Sposetti, G., Mackinnon, I. J., & Barengo, N. C. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.995636 · Cited by 3
Engeli, S., & Jordan, J. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000449846.91046.ac · Cited by 3
Jayasinghe, K. N. U., Greener, V., & Feher, M. D. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.092 · Cited by 3
Sodium-glucose cotransporter-2 inhibitors: Moving beyond the glycemic treatment goal
Garodia, N., Gupta, V., Canovatchel, W. J., Lokesh, B., & Santani, R. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_85_17 · Cited by 3
Das, G. C., Surya, A., & Abusahmin, H. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818771434 · Cited by 3
Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes
Siamashvili, M., & Davis, S. N. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1967320 · Cited by 3
Obesity Pharmacotherapy: a Review of Current Practices and Future Directions
Schmitz, S. H., Tchang, B. G., & Shukla, A. P. (2023) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-023-00409-1 · Cited by 3
An, J., Kim, D., Kim, S. J., Kim, H. J., & Na, D. H. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-024-00688-5 · Cited by 3
Diabetes management: Beyond hemoglobin A1c
Makin, V., & Lansang, M. C. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.18031 · Cited by 3
Baruah, M. P., & Kalra, S. (2019) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2019.15.2.113 · Cited by 3
Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease
Koo, B. K., & Lim, S. K. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch13 · Cited by 3
Akhanlı, P., Hepşen, S., ARSLAN, İ. E., Düğer, H., Bostan, H., Kızılgül, M., Uçan, B., & Çakal, E. (2023) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5683 · Cited by 2
Storey, R. F., Deanfield, J. E., James, S. K., Ajjan, R., Eriksson, N., Erlinge, D., de Belder, M., Gale, C. P., Zaman, A., Hofmann, R., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040327 · Cited by 4
Self-citationSaengklub, N., Kijtawornrat, A., & Hamlin, R. L. (2025) · Veterinary and Animal Science · doi:10.1016/j.vas.2025.100510 · Cited by 2
Checa-Ros, A., Okojie, O. J., Steib, N., Bellasi, A., Salvador-Martínez, P., Isabel, F., & D’Marco, L. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04965-6 · Cited by 2
Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial
Andersen, C. F., Larsen, J. H., Omar, M., Nouhravesh, N., Kistorp, C., Tuxen, C., Knop, F. K., Madsen, P. L., Forman, J. L., Davidovski, F. S., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag010 · Cited by 2
Safety Profile of SGLT-2 Inhibitors in Older Adults: A Systematic Review and Network Meta-Analysis
Sridharan, K., & Sivaramakrishnan, G. (2026) · Medical Sciences · doi:10.3390/medsci14010153 · Cited by 4
Habas, E., Rayani, A., Habas, A., Alarbi, K., Habas, A., Baghi, M., Habas, E., Errayes, E., Hamad, A., & Elzouki, A. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2688578 · Cited by 2
Steen, O., & Goldenberg, R. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.11.008 · Cited by 2
RetractedDapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM
Nada, A. M., & Younan, M. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821995364 · Cited by 2
Helu, N. K., & Nattouf, A. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00755 · Cited by 2
Tomlinson, B., & Chan, P. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2341882 · Cited by 2
Ghosh, S., Mukhopadhyay, M., Agrawal, M. B., Shahid, M., Lamba, M., Jain, S., Prasad, A., Gupta, A., Kesarkar, R. N., Warrier, S. B., et al. (2024) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_24_24 · Cited by 2
Abiri, B., Ahmadi, A. R., Hosseinpanah, F., Valizadeh, A., Zarghi, A., & Valizadeh, M. (2024) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-024-01692-2 · Cited by 2
El-Din, Z. S., Afify, M., Zayed, E., Elsabaawy, D. M., Tharwa, E., Elsharawy, A., Abdelsameea, E., & Rady, M. A. (2024) · World Journal of Experimental Medicine · doi:10.5493/wjem.v14.i4.95272 · Cited by 3
Metadata
- Authors
- Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S.
- Affiliations
- Karolinska University Hospital (SE)
- Uppsala University Hospital (SE)
- Aintree University Hospital (GB)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- Corresponding author
- Bolinder, Jan
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-03-01
- Volume
- 97
- Issue
- 3
- Pages
- 1020-1031
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2167245776
- Cited by
- 867
- References
- 36
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 51 · 2023: 76 · 2022: 76 · 2021: 70 · 2020: 85 · 2019: 54 · 2018: 53 · 2017: 72 · 2016: 62 · 2015: 53 · 2014: 79 · 2013: 42 · 2012: 17
- FWCI
- 48.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, weight loss, body composition, fat mass, visceral adipose tissue, subcutaneous adipose tissue, hepatic fat content, metformin, inadequate glycemic control, waist circumference, fluid balance, urinary glucose excretion, glycemic control
- MeSH terms
- Adipose Tissue, Adult, Aged, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucosides, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Body Mass Index, Treatment Outcome, Body Fat Distribution, Sodium-Glucose Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
